Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02935660
Other study ID # C-16-EN13
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2016
Est. completion date June 2017

Study information

Verified date September 2023
Source Cutera Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multi-center study to evaluate the safety and efficacy of an investigational version of the Cutera enlighten laser that offers multiple wavelengths for tattoo removal


Description:

A multi-center prospective, open-label, uncontrolled pivotal study to evaluate the safety and efficacy of an investigational version of the Cutera enlighten laser that offers multiple wavelengths for tattoo removal.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Female or Male, 18 to 65 years of age (inclusive). - Fitzpatrick Skin Type I - VI. - Target tattoo contains single or multi-color ink, and must include blue and/or green ink. - Target tattoos must be older than 1 year. - Target treatment area not to exceed 12 square inches. - Subject must be able to read, understand and sign the Informed Consent Form. - Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions. - Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area starting 2 to 4 weeks before the treatment and/or every day for the duration of the study, including the follow-up period. - Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes. - Agree to not undergo any other procedure(s) for tattoo removal during the study (as applicable). - Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study. Exclusion Criteria: - Participation in a clinical trial of a drug or another device in the target area during the study. - Target tattoo contains only black ink. - History of allergic reaction to pigments following tattooing. - History of allergy to local anesthetics. - History of allergy to topical antibiotics. - History of malignant tumors in the target area. - Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles. - Pregnant and/or breastfeeding. - Having an infection, dermatitis or a rash in the treatment area. - Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension. - Suffering from coagulation disorders or taking prescription anticoagulation medications. - History of keloid scarring, hypertrophic scarring or of abnormal wound healing. - History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications per investigator's discretion. - History of vitiligo, eczema, or psoriasis. - History of connective tissue disease, such as systemic lupus erythematosus or scleroderma. - History of seizure disorders due to light. - Any use of medication that is known to increase sensitivity to light according to Investigator's discretion. - History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen. - History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer. - History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation. - Systemic use of corticosteroid or isotretinoin, as applicable, within 6 months of study participation. - Anytime in life, having used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus. - Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study. - Current smoker or history of smoking within 6 months of study participation. - As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
enLighten Laser
Laser tattoo removal treatment

Locations

Country Name City State
United States Cutera Research Clinic Brisbane California
United States Skin Care Physicians Chestnut Hill Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Cutera Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tattoo Clearing as Rated by Blinded Evaluator Percentage of subjects with tattoo ink clearing of at least 50% or more at 6 weeks post-final treatment 6 weeks post-final treatment, approximately 7 months after study start
Secondary Degree of Overall Tattoo Ink Clearing at 6 Weeks Post-final Treatment as Assessed by the Investigator (Physician's Global Assessment of Improvement). Physician's Global Assessment of Improvement (min=0; max=4) Higher scores mean better outcomes 6 weeks post-final treatment, approximately 7 months after study start
Secondary Subject Satisfaction Levels at 6 Weeks Post-final Treatment 6 weeks post-final treatment, approximately 7 months after study start
Secondary Subject Pain During Treatment Numeric Pain Rating Scale (Min=0; Max=10) Higher scores indicate worse outcomes Pain values from all treatment visits and subjects were combined and averaged. Reported by subject at the end of each treatment visit, up to 5 months
See also
  Status Clinical Trial Phase
Completed NCT02912507 - Split-tattoo Study Comparing the Safety and Efficacy of 670nm Picosecond Laser Versus 755 nm for Tattoo Removal N/A
Completed NCT01973166 - Study of Picosecond and Nanosecond Q-switched Lasers for Tattoo Removal N/A
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT05102617 - Post Market Usability Evaluation Of The PicoSure Pro Device N/A
Completed NCT02910505 - A Study of a Novel Multi-Wavelength Laser for Tattoo Removal N/A
Completed NCT03290547 - Pilot Study of Multi-wavelength Laser for Tattoo Removal N/A
Completed NCT02244554 - Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal N/A
Completed NCT01624688 - Optimizing Tattoo Removal: a Side-by-side Comparison in the Search for One Treatment Tattoo Removal N/A
Recruiting NCT03866304 - Performance Evaluation of Tattoo Removal N/A
Terminated NCT02756806 - A Clinical Evaluation for Tattoo Removal N/A